• GSK126 EZH2 Inhibitor: Bridging Mechanism to Clinical Epigen

  2026-04-28

  Explore how GSK126, a potent EZH2 inhibitor, is revolutionizing cancer epigenetics research by precisely targeting PRC2-mediated gene silencing. This in-depth analysis uniquely bridges mechanistic insights with translational and assay strategy.

• Aztreonam in Research: Beyond Resistance Modeling & Enzyme M

  2026-04-28

  Explore the advanced research applications of Aztreonam, a monocyclic β-lactam antibiotic, in dissecting Gram-negative resistance, bone marrow inhibition, and hepatic enzyme modulation. This article delivers a deeper perspective on assay design and translational impact, grounded in recent molecular epidemiology.

• Plant Exosome-like Nanovesicles Alleviate Testicular Injury

  2026-04-27

  This study identifies plant-derived exosome-like nanovesicles from Cistanche deserticola as modulators of cell cycle arrest in Sertoli cells, mitigating cyclophosphamide-induced testicular injury. The findings highlight a novel molecular pathway for reproductive protection and suggest translational avenues for male fertility preservation strategies.

• T7 RNA Polymerase: Precision In Vitro Transcription Unlocked

  2026-04-27

  APExBIO’s T7 RNA Polymerase, a recombinant enzyme expressed in E. coli, empowers reliable, high-yield RNA synthesis across vaccine production, antisense, and structural studies. This article delivers actionable workflows, protocol enhancements, and troubleshooting strategies rooted in the latest research and comparative insights.

• Rapamycin (Sirolimus): Applied mTOR Inhibition in Bench Rese

  2026-04-26

  Rapamycin (Sirolimus) offers precise, nanomolar mTOR inhibition for dissecting AKT/mTOR and related signaling pathways in cancer, immunology, and mitochondrial disease research. This article translates the latest mechanistic insights and workflow refinements into actionable protocols, tackling troubleshooting and maximizing reproducibility with APExBIO's trusted formulation.

• CRISPRa Enables Splice Variant Analysis in Patient Fibroblas

  2026-04-25

  Terkelsen et al. (2024) demonstrate a CRISPR activation (CRISPRa) approach that induces expression of clinically relevant genes in skin fibroblasts, allowing the functional assessment of splice-altering variants even for genes not naturally expressed in these cells. This innovation streamlines rare-disease diagnostics by coupling targeted gene induction with advanced sequencing, overcoming key limitations of tissue accessibility.

• Pexidartinib (PLX3397): Redefining Macrophage Modulation in

  2026-04-24

  Explore how Pexidartinib (PLX3397) advances cancer research through precise tumor microenvironment macrophage modulation and CSF1R-mediated signaling inhibition. This article reveals new assay strategies and translational insights distinct from standard product overviews.

• Z-YVAD-FMK: Caspase-1 Inhibitor Workflows in Pyroptosis & Ca

  2026-04-24

  Z-YVAD-FMK empowers precise modulation of caspase-1 in apoptosis and pyroptosis assays, enabling high-selectivity analysis of inflammasome involvement in cancer and inflammation. This practical guide translates the latest research into optimized protocols, troubleshooting strategies, and actionable insights for advanced cell death studies.

• RepSox in Stem Cell Platelet Differentiation: Mechanisms & P

  2026-04-23

  Explore how RepSox, a potent ALK5 inhibitor, enables advanced induced pluripotent stem cell (iPSC) platelet production. This article uniquely deciphers practical protocols and mechanistic insights for cost-effective, high-yield differentiation.

• RBMS1 Loss Enables PD-L1 Blockade in Triple-Negative Breast

  2026-04-23

  This study identifies RBMS1 as a critical regulator of PD-L1 stability and immunosuppression in triple-negative breast cancer (TNBC). By elucidating the molecular mechanism connecting RBMS1, B4GALT1-mediated glycosylation, and PD-L1 degradation, the research offers a novel combinatorial approach to enhance anti-tumor immunity and improve immunotherapy outcomes in TNBC.

• USP42 Drives Breast Cancer Progression by Suppressing JNK/p3

  2026-04-22

  This study identifies USP42 as a key promoter of breast cancer progression through inhibition of JNK/p38-mediated apoptosis. By dissecting molecular mechanisms and employing robust in vitro and in vivo models, the work highlights USP42 as a potential therapeutic target and advances understanding of deubiquitinating enzymes in breast cancer.

• EZH1/EZH2 Inhibition Boosts Adoptive T Cell Immunotherapy Ef

  2026-04-22

  Porazzi et al. demonstrate that pharmacological inhibition of EZH1 and EZH2 can reprogram tumor cells to a more immunogenic state, thereby enhancing the efficacy of CAR-T and TCR-T cell therapies in both liquid and solid cancer models. This work provides a mechanistic and preclinical foundation for integrating dual EZH1/2 inhibition strategies, such as Valemetostat, into next-generation epigenetic cancer therapy and adoptive cell immunotherapy protocols.

• 40-Hz Light Flicker Enhances Retinal Amyloid Clearance via M

  2026-04-21

  This study demonstrates that 40-Hz light flicker boosts retinal microglial activation and MHC-II expression, leading to enhanced clearance of amyloid-β deposits in aged mice. The findings highlight a non-invasive strategy for addressing metabolic waste in retinal aging, and underscore the importance of microglial modulation—validated using minocycline hydrochloride inhibition—in age-related retinal disease models.

• SGI-1027: Innovative DNA Methyltransferase Inhibition in Can

  2026-04-21

  Explore how SGI-1027, a potent DNA methyltransferase inhibitor, is reshaping cancer epigenetics through novel mechanisms and synergy with targeted therapies. This article delves into advanced research applications and unique cytotoxic properties, setting it apart from prior content.

• Synergistic Antibacterial Action of Copper and Hexetidine In

  2026-04-20

  This study demonstrates a marked synergistic antibacterial effect when copper and hexetidine are combined against Streptococcus sobrinus and Streptococcus sanguis. The findings provide quantitative evidence for optimizing antibacterial strategies in oral microbiology, with implications for designing more effective antimicrobial protocols.

451 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page